{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:30:28Z","timestamp":1727325028231},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,25]]},"DOI":"10.7759\/cureus.70196","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:34:55Z","timestamp":1727300095000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of the Safety of Tofacitinib Among Patients With Psoriasis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Saad","family":"Alqahtani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basel H","family":"Bakhamees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Layan M","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariyah A","family":"Alyahya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waleed Khalid Z","family":"Alghuyaythat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah K","family":"Alabdulqader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Aldossary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuruq Talea B","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talal A","family":"Alsulami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman A","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A","family":"Alaamer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of psoriasis and comorbid diseases: a narrative review","volume":"13","author":"Bu J","year":"2022","unstructured":"Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of psoriasis and comorbid diseases: a narrative review. Front Immunol. 2022, 13:880201. 10.3389\/fimmu.2022.880201","journal-title":"Front Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil SK","year":"2016","unstructured":"Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016, 38:11-27. 10.1007\/s00281-015-0539-8","journal-title":"Semin Immunopathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0257","article-title":"Psoriasis: a brief overview","volume":"21","author":"Raharja A","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021, 21:170-173. 10.7861\/clinmed.2021-0257","journal-title":"Clin Med (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0292","article-title":"Immunotherapy in psoriasis","volume":"13","author":"Landeck L","year":"2021","unstructured":"Landeck L, Sabat R, Ghoreschi K, Man XY, Fuhrmeister K, Gonzalez-Martinez E, Asadullah K. Immunotherapy in psoriasis. Immunotherapy. 2021, 13:605-619. 10.2217\/imt-2020-0292","journal-title":"Immunotherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky AM","year":"2022","unstructured":"Shawky AM, Almalki FA, Abdalla AN, Abdelazeem AH, Gouda AM. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics. 2022, 14:1001. 10.3390\/pharmaceutics14051001","journal-title":"Pharmaceutics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: a review","volume":"10","author":"Kvist-Hansen A","year":"2020","unstructured":"Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb). 2020, 10:29-42. 10.1007\/s13555-019-00347-w","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16433","article-title":"Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies","volume":"34","author":"Merola JF","year":"2020","unstructured":"Merola JF, Papp KA, Nash P, et al.. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. J Eur Acad Dermatol Venereol. 2020, 34:2809-2820. 10.1111\/jdv.16433","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","volume":"2014","author":"Hsu L","year":"2014","unstructured":"Hsu L, Armstrong AW. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis. J Immunol Res. 2014, 2014:283617. 10.1155\/2014\/283617","journal-title":"J Immunol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-015-0025-y","article-title":"Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis","volume":"15","author":"Valenzuela F","year":"2015","unstructured":"Valenzuela F, Papp KA, Pariser D, et al.. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis. BMC Dermatol. 2015, 15:8. 10.1186\/s12895-015-0025-y","journal-title":"BMC Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette R","year":"2015","unstructured":"Bissonnette R, Iversen L, Sofen H, et al.. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol. 2015, 172:1395-1406. 10.1111\/bjd.13551","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339:b2700. 10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13956","article-title":"Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial","volume":"44","author":"Abe M","year":"2017","unstructured":"Abe M, Nishigori C, Torii H, et al.. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: subgroup analyses from a randomized, placebo-controlled phase 3 trial. J Dermatol. 2017, 44:1228-1237. 10.1111\/1346-8138.13956","journal-title":"J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang J","year":"2017","unstructured":"Zhang J, Tsai TF, Lee MG, et al.. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci. 2017, 88:36-45. 10.1016\/j.jdermsci.2017.05.004","journal-title":"J Dermatol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez H","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R, et al.. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015, 386:552-561. 10.1016\/S0140-6736(14)62113-9","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp KA","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, et al.. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015, 173:949-961. 10.1111\/bjd.14018","journal-title":"Br J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp KA","year":"2012","unstructured":"Papp KA, Menter A, Strober B, et al.. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012, 167:668-677. 10.1111\/j.1365-2133.2012.11168.x","journal-title":"Br J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1013534","article-title":"Tofacitinib for the treatment of moderate-to-severe psoriasis","volume":"11","author":"Chiricozzi A","year":"2015","unstructured":"Chiricozzi A, Faleri S, Saraceno R, Bianchi L, Buonomo O, Chimenti S, Chimenti MS. Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Rev Clin Immunol. 2015, 11:443-455. 10.1586\/1744666X.2015.1013534","journal-title":"Expert Rev Clin Immunol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1195812","article-title":"Tofacitinib for the treatment of psoriasis","volume":"17","author":"Galluzzo M","year":"2016","unstructured":"Galluzzo M, D'Adamio S, Servoli S, Bianchi L, Chimenti S, Talamonti M. Tofacitinib for the treatment of psoriasis. Expert Opin Pharmacother. 2016, 17:1421-1433. 10.1080\/14656566.2016.1195812","journal-title":"Expert Opin Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.023","article-title":"Herpes zoster in psoriasis patients treated with tofacitinib","volume":"77","author":"Winthrop KL","year":"2017","unstructured":"Winthrop KL, Lebwohl M, Cohen AD, et al.. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017, 77:302-309. 10.1016\/j.jaad.2017.03.023","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka K","year":"2004","unstructured":"Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004, 5:253. 10.1186\/gb-2004-5-12-253","journal-title":"Genome Biol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz DM","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017, 16:843-862. 10.1038\/nrd.2017.201","journal-title":"Nat Rev Drug Discov"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0596-y","article-title":"Tofacitinib: a new oral therapy for psoriasis","volume":"38","author":"Azevedo A","year":"2018","unstructured":"Azevedo A, Torres T. Tofacitinib: a new oral therapy for psoriasis. Clin Drug Investig. 2018, 38:101-112. 10.1007\/s40261-017-0596-y","journal-title":"Clin Drug Investig"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2013.03.002","article-title":"Tofacitinib and other kinase inhibitors in the treatment of psoriasis","volume":"104","author":"Ortiz-Ib\u00e1\u00f1ez K","year":"2013","unstructured":"Ortiz-Ib\u00e1\u00f1ez K, Alsina MM, Mu\u00f1oz-Santos C. Tofacitinib and other kinase inhibitors in the treatment of psoriasis. Actas Dermosifiliogr. 2013, 104:304-310. 10.1016\/j.adengl.2013.03.002","journal-title":"Actas Dermosifiliogr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger J","year":"2016","unstructured":"Krueger J, Clark JD, Su\u00e1rez-Fari\u00f1as M, et al.. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study. J Allergy Clin Immunol. 2016, 137:1079-1090. 10.1016\/j.jaci.2015.12.1318","journal-title":"J Allergy Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/297564-assessment-of-the-safety-of-tofacitinib-among-patients-with-psoriasis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:34:56Z","timestamp":1727300096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/297564-assessment-of-the-safety-of-tofacitinib-among-patients-with-psoriasis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.70196","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}